Xilio Development Total Stockholder Equity Over Time
| XLO Stock | USD 1.01 0.02 2.02% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Xilio Development Performance and Xilio Development Correlation. Xilio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xilio Development. If investors know Xilio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xilio Development listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 0.105 | Return On Assets (0.53) | Return On Equity (1.71) |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xilio Development's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare Xilio Development and related stocks such as Connect Biopharma, Tyra Biosciences, and RAPT Therapeutics Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTB | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (157 M) | 272.6 M | (463.8 M) | 101 M | 106.1 M |
| TYRA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (13.6 M) | 301.7 M | (95.7 M) | 204.3 M | 214.5 M |
| RAPT | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | 64 M | 73.1 M | 104.2 M | 186.4 M | 245.2 M | 147 M | 119 M |
| MLYS | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (22.9 M) | (52.3 M) | 241.2 M | 253.2 M |
| EWTX | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (33.4 M) | 274.4 M | 346.7 M | 318.8 M | 195.7 M |
| IKNA | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (61.5 M) | (101 M) | 207.9 M | 147 M | 169.8 M | 178.2 M |
| DSGN | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (11.3 M) | 382.1 M | 327.3 M | 277.7 M | 213.9 M |
| ANEB | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | 21.4 M | 15.1 M | 10.6 M | 3.8 M | 3.6 M |
| ANTX | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | (20.3 M) | (47.4 M) | 95.4 M | 124.7 M | 130.9 M |
| AVTE | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (13.3 M) | 172.4 M | 126.7 M | 109.5 M | 86.2 M |
| ADAG | (41 M) | (41 M) | (41 M) | (41 M) | (41 M) | (41 M) | (41 M) | (41 M) | (41 M) | (57 M) | (89.4 M) | 156.6 M | 83.1 M | 70.6 M | 74.1 M |
| MOLN | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 148.5 M | 151.8 M | 135.8 M | 116.7 M | 91.7 M | 54.1 M | 107.2 M | 107.3 M | 235.2 M | 176.4 M | 137.3 M |
| MNOV | 8.1 M | 23.5 M | 14.9 M | 25.4 M | 22 M | 32.8 M | 34.5 M | 38.6 M | 73.1 M | 74.9 M | 71.3 M | 83.7 M | 70.2 M | 62.4 M | 50.9 M |
| CSBR | 440 K | (5.3 M) | 7.6 M | 3.2 M | 8.1 M | 238 K | 400 K | (25 K) | 2.2 M | 5.3 M | 7.4 M | 9.1 M | 4.6 M | (1.9 M) | (1.8 M) |
Xilio Development and related stocks such as Connect Biopharma, Tyra Biosciences, and RAPT Therapeutics Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| Xilio Development | XLO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.01
Check out Xilio Development Performance and Xilio Development Correlation. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Xilio Development technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.